Long Lived, Virus Resistant Resident Memory T Cells
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Vaccines that deposit memory T cells within the lung, gut and genital tract hold enormous therapeutic potential, as these mucosal surfaces are major portals of entry into the body for many viruses. However, the accumulation of large numbers of T cells within the mucosal tissue may increase the number of target cells for T cell trophic viruses (eg HIV) to infect. We will explore factors that are important in the generation of mucosal memory T cells that are also resistant to virus infection.
Host-pathogen Interaction: The Battle For Supremacy
Funder
National Health and Medical Research Council
Funding Amount
$480,014.00
Summary
This grant will provide salary support for Dr Rowena Bull. Dr Bull's research is focused on understanding the disease process between the human host and the infecting virus. The outcomes of this research will be used to find novel ways to fight viral infections with vaccines and drugs.
Melanoma is a devastating disease. We are investigating new ways to treat and cure this form of cancer. Specifically, we are identifying how the body’s immune system interacts with melanoma and exploring new ways to use one’s own immune cells to destroy the cancer. This is achieved by understanding the interplay between various immune cells during melanoma and current therapies. This knowledge allows us to manipulate the immune cells providing better treatment.
Combination Immunotherapeutic Strategies For Haematological Cancers
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a novel vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymph ....Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a novel vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymphoma.Read moreRead less
Utilising Human Primary Immunodeficiencies To Study Lymphocyte Differentiation
Funder
National Health and Medical Research Council
Funding Amount
$429,346.00
Summary
Human immunodeficiencies are diseases arising from naturally occurring mutations. In this instance, the specific genes mutated in the immunodeficiencies we study have been identified. However, it is unclear how defects in these genes make an individual manifest as an immune deficient state, rendering them vulnerable to disease. By studying immune cells from these individuals we hope to uncover the normal function of these genes and subsequently provide for new therapies for these conditions.
Understanding And Modulating The Human Immune System
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
T cells are the sentinels of our immune system continually scanning our tissue for abnormalities and eliminating threats in many forms. They are our second and last line of defence against microorganisms and cancer. Unfortunately, T cells can also cause harm through accidental crossreactvity or overzealous function. My work is directed at understanding how T cells work and how they can be controlled using drugs and gene therapy. If we can ‘tune’ the power of this master immune lineage we can unl
The Inflammasome In Host Defence And Autoinflammation
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Inflammation is one of the bodies first responses to infection. The inflammasome is a protein complex that activates pro-inflammatory cytokines as part of this process. We are investigating pathogens that activate a specific inflammasome complex, and also an inflammatory disease it may cause when activated accidentally, in the absence of infection. We are also investigating pathways that keep this inflammation in check, and how pathogens might hijack these anti-inflammatory pathways to promote i ....Inflammation is one of the bodies first responses to infection. The inflammasome is a protein complex that activates pro-inflammatory cytokines as part of this process. We are investigating pathogens that activate a specific inflammasome complex, and also an inflammatory disease it may cause when activated accidentally, in the absence of infection. We are also investigating pathways that keep this inflammation in check, and how pathogens might hijack these anti-inflammatory pathways to promote infection.Read moreRead less